The project contributes to national HIV surveillance and focuses on the changing epidemiology of HIV/AIDS after the introduction of new therapies in 1995. ClinSurv HIV is designed as an open multicentre observational cohort study of HIV-infected patients. Anonymized data on diagnoses, treatment and laboratory parameters are collected in a standardized
format. Data are currently sampled biannually via 11 centres specializing in HIV diagnosis and care within the legal framework of the German Protection against Infection Act [Infektionsschutzgesetz (IfSG)]. A total of 14 874 patients were enrolled in the study by 30 June 2009. Of these, 10 221 patients (68.7%) were enrolled after 1 January 1999 and
6006 patients (40.4%) were known to have been diagnosed as positive for HIV before 1999. Evaluation indicators, 17-AAG chemical structure such as the number of newly enrolled patients per half-year period, loss to follow-up, completeness of data per case, availability of data per possible clinical contact, and internal quality control parameters, show a very stable evolution in the cohort, which although open, can be observed. Comparison with the national HIV surveillance data suggests a high degree of representativeness according to major demographic variables. Bearing in mind the obvious strengths and weaknesses discussed, the German ClinSurv HIV cohort provides a broad range of research opportunities in the field of Selleck MAPK Inhibitor Library HIV/AIDS both within Germany and in international collaborative research. As in other Western European countries, the total number of reported newly diagnosed HIV infections has increased markedly since 2001 in Germany, especially among men having sex with men (MSM) [1–3]. The number of
newly diagnosed cases of AIDS, however, decreased between 2000 and 2007 in the Western European region . At the end of 2009, the prevalence of HIV infections and AIDS reached an estimated 67 000 (range 64 000–70 000) people living with HIV/AIDS (PLWHA) in Germany, of whom nearly 11 300 were living with AIDS . National HIV surveillance in Germany is based on mandatory reports of newly diagnosed cases Sirolimus price of HIV infection and voluntary reporting of AIDS cases to the Robert Koch Institute (RKI), a federal institute under the umbrella of the German Ministry of Health [Bundesministerium für Gesundheit (BMG)]. Since 2001, surveillance of HIV/AIDS has been regulated by the national Protection against Infection Act [Infektionsschutzgesetz (IfSG)] . Follow-up of clinical care of patients infected with HIV in Germany requires additional surveillance instruments. In particular, a cohort study design complements the ‘traditional’ cross-sectional surveillance.